Follow the people · Insider
David Zawitz
David Zawitz files insider transactions with the SEC as a chief operating officer of Verrica Pharmaceuticals (VRCA). We hold 1 disclosed purchase or sale filed since 9 December 2024, 1 of them in the last 90 days.
- Files forVRCA
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure18 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 9 December 2024 — 17 August 2026Chief Operating Officer · Verrica Pharmaceuticals (VRCA)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
5 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 6,000 shares of Verrica PharmaceuticalsSEC Form 418 August 2026Common Stock · traded 17 August 2026 · filed 18 August 2026
- was granted 171,340 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 49 June 2026Employee Stock Option (right to buy) · traded 5 June 2026 · filed 9 June 2026
- ▲ bought on the open market 2,500 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 425 November 2025Series C Warrant (right to buy) · traded 25 November 2025 · filed 25 November 2025
- ▲ bought on the open market 10,000 shares of Verrica PharmaceuticalsSEC Form 425 November 2025Common Stock · traded 25 November 2025 · filed 25 November 2025
- was granted 950,000 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 49 December 2024Employee Stock Option (right to buy) · traded 9 December 2024 · filed 9 December 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.